Tailoring ECP Treatment for Specific Patients’ Needs June

The Goal

The goal of this practical course is to provide expert information on important aspects that need to be considered when treating specific patient populations on both prescription of ECP and delivery of the therapy. The interactive setting fosters discussion between peers.

Agenda

Download Agenda PDF

Day 1 - 15 June 2026

13:30 – 13:45
Welcome and Introduction - Clinical Service, Therakos

13:45 – 14:00
Medical Device Regulation for THERAKOS™ CELLEX™ Photopheresis System in 2026 - Carlota Bernal Boronat, Medical Affairs, Therakos

14:00 – 14:45
Overview of acute and chronic GvHD in low body weight patients over 3 yrs old – Biology, diagnosis, grading, and impact of the disease - Dr. Cristina Diaz de Heredia

14:45 – 15:30
Treatment of acute and chronic GvHD in children over 3 yrs old and adolescents – The role of ECP and its challenges in low body weight patients - Dr. Cristina Diaz de Heredia

An Overview of ECP and Its Clinical Applications

15:30 – 16:00
General considerations on ECP and its proposed mechanism of action - Dr. Veronica Pons

16:00 – 16:15
ECP: From prescription to treatment – Logistical aspects - Dr. Andrea Espasa

16:15 – 16:30
Interactive discussion - All

16:30 – 17:00
Clinical considerations for ECP use in low body weight patients - Dr. Andrea Espasa

17:00 – 17:15
Interactive discussion - All

19:30
Meeting in the lobby

20:00
Dinner

Day 2 - 16 June 2026

08:30 – 09:00
Management of specific patient conditions - Dr. Andrea Espasa

09:00 – 09:30
Optimising venous access in ECP: Clinical decision-making and best practices - Dr. Veronica Pons

09:30 – 10:00
Customisation of the blood prime procedure - Dr. Veronica Pons

10:00 – 10:15
Interactive discussion - All

10:15 – 11:45
ECP treatment experience in low body weight patients over 3 yrs old – Practical case - Dr. Veronica Pons & Dr. Andrea Espasa

11:45 – 12:00
Final remarks and close - Faculty

ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease, LBW: Low Body Weight, MDR: Medical Device Regulation

Please see the THERAKOS™ CELLEX™ Photopheresis System operator’s Manual for indications, contraindications, warnings, precautions, adverse reactions, and other important information.

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd
This information is not intended for healthcare professionals based in Europe and the Middle East.

Hosted by

Dr. Cristina Diaz de Heredia

Dr. Andrea Espasa

Dr. Veronica Pons

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd.

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

Explore related courses

Jun 18 - 19, 2026

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

The Tirol Kliniken, Innsbruck, Austria

Find out more

Sep 10 - 11, 2026

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

The Tirol Kliniken, Innsbruck, Austria

Find out more

Nov 23 - 24, 2026

Tailoring ECP Treatment for Specific Patients’ Needs

Vall d'Hebron Barcelona University Hospital, Banc de Sang i Teixits, Barcelona, Spain

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Tailoring ECP Treatment for Specific Patients’ Needs

The Goal

Agenda

Day 1 - 15 June 2026

Day 2 - 16 June 2026

Hosted by

Brought to you by the Therakos Institute

Explore related courses

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

Tailoring ECP Treatment for Specific Patients’ Needs

Sign in to register your interest

Register your interest in attending